What is Ipsen S.A. (IPSEY)?

Ipsen S.A. (IPSEY) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of IPSEY?

The current price of IPSEY is $44.35. Prices are updated in real time on Stocks360.

What is IPSEY's price-to-earnings (PE) ratio?

IPSEY's trailing twelve-month PE ratio is 25.13, based on current price and earnings per share data available on Stocks360.

What is IPSEY's market capitalization?

IPSEY's market capitalization is $58,649,127,429.00, placing it in the large-cap tier.

Does IPSEY pay a dividend?

Yes. IPSEY has a trailing twelve-month dividend yield of 0.01%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Ipsen S.A. (IPSEY)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$44.35

Market Cap

$58.65B

PE (TTM)

25.13

EPS (TTM)

N/A

Dividend Yield

1.03%

Beta

0.32

Day Range

$42.70 – $44.35

52-wk Range

$28.55 – $51.10

Avg Volume

N/A

Volume

50.00

Ipsen S.A. (IPSEY) is a publicly traded company in the Healthcare sector. Latest price: $44.35. Market cap $58.65B. Trailing PE 25.13. Dividend yield 1.03%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $35.42 2026-10-29 · $44.35 (+25.22%)

Earnings

Most Recent

Jul 30, 2026

EPS $2.11 vs est. $1.86

Beat by $0.25

Next Earnings

Feb 11, 2027

EPS estimate $2.22

Proprietary Signals

Signal snapshot temporarily unavailable.

About Ipsen S.A.

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of reco…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	25.13×
P/S (TTM)	3.18×
P/B	2.74×
PEG	1.75×
P/FCF (TTM)	10.51×
EV / EBITDA	6.13×
EV / Sales	2.94×
Earnings Yield	3.98%
Free Cash Flow Yield	9.52%
Dividend Yield	1.03%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$11.88B
Revenue (TTM)	$4.05B
Net Income (TTM)	$512.60M
Free Cash Flow (TTM)	$1.12B
Net Debt	-$1.01B
Working Capital	$1.67B
Gross Margin	67.52%
Operating Margin	30.13%
Net Margin	12.67%
Return on Equity	11.33%
Return on Invested Capital	14.87%